Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit .BOSTON--(BUSINESS WIRE)--Nov. 27, 2024--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Adam Crystal, M.D., Ph.D., President, Research & Development of Tango Therapeutics, is scheduled to present at the Piper Sandler 36th Annual Healthcare Conference on Thursday, December 5, 2024 at 1:30 PM ET.
波士頓--(美國商業資訊)--2024年11月27日--致力於發現和提供下一代精準癌症藥物的臨牀階段生物技術公司Tango Therapeutics, Inc.（納斯達克股票代碼：TNGX）今天宣佈，Tango Therapeutics研發總裁亞當·克里斯塔爾萬博士定於12月5日星期四出席派珀·桑德勒第36屆年度醫療保健會議。2024 年美國東部時間下午 1:30
A live webcast of the presentation will be available under the "Events & Presentations" tab on the "Investors" page on the Company's website on the day of the event. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.
活動當天，將在公司網站 「投資者」 頁面的 「活動和演講」 選項卡下提供演示的網絡直播。網絡直播的重播將在演示結束後的90天內在公司網站上存檔。
About Tango Therapeutics
關於探戈療法
Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit .
Tango Therapeutics是一家處於臨牀階段的生物技術公司，致力於發現新的藥物靶標並提供用於治療癌症的下一代精準醫學。Tango採用以患者爲起點和終點的方法，利用合成殺傷力的遺傳原理來發現和開發針對癌症關鍵靶標的療法。欲了解更多信息，請訪問。
View source version on businesswire.com:
在 businesswire.com 上查看源版本：
Investor Contact:
Sam Martin/Andrew Vulis
Argot Partners
tango@argotpartners.com
Media Contact:
Amanda Brown Galgay
SVP, Corporate Communications, Tango Therapeutics
media@tangotx.com
投資者聯繫方式：
山姆·馬丁/安德魯·瓦利斯
Argot 合作伙伴
tango@argotpartners.com
媒體聯繫人：
阿曼達·布朗·加爾蓋
Tango Therapeutics 企業傳播高級副總裁
media@tangotx.com
Source: Tango Therapeutics, Inc.
資料來源：Tango Therapeutics, Inc.
